CMS Revises Its Pricing Determination for AlloMap(R)


Reimbursement for Heart Transplant Surveillance Testing to Remain At Previous Level

Decision is Victory for Transplant Community

BRISBANE, Calif., Nov. 17, 2015 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance solutions for transplant recipients, today commended the Centers for Medicare and Medicaid Services (CMS) for revising the 2016 pricing determinations for AlloMap in the final Clinical Laboratory Fee Schedule (CLFS), released by CMS on November 17 2015. Final pricing determinations for the 2016 CLFS include a payment rate for AlloMap of $2,821, which is the same as the existing rate set by a number of Medicare Administrative Contractors (MAC) including Noridian Administrative Services, Cigna Governmental Services, and Palmetto GBA.

The revised pricing determination for AlloMap is a victory for personalized medicine, the transplant community and is a positive example of the CMS public comment process that allowed stakeholder input to inform final decision making. Stakeholders - patients, providers, industry groups, and professional societies - mobilized to support revision of pricing for AlloMap during the open comment period. The CMS Advisory Panel on Clinical Diagnostic Laboratory Tests met on October 19, 2015 and, once again, issued a unanimous 12-0 vote in support of using the gapfill methodology to price AlloMap. Continue reading